The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

Bernstein analyst Miki Sogi maintained a Buy rating on Chugai Pharmaceutical Co (CHGCF – Research Report) yesterday and set a price target of ...